<DOC>
	<DOCNO>NCT02128308</DOCNO>
	<brief_summary>This study aim investigate pharmacokinetic characteristic second-line anti-tuberculosis agent oral/intramuscular administration healthy male volunteer .</brief_summary>
	<brief_title>Clinical Trial Investigate Pharmacokinetics Second-Line Anti-Tuberculosis Agents</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Aminosalicylic Acid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Cycloserine</mesh_term>
	<mesh_term>Antitubercular Agents</mesh_term>
	<mesh_term>Prothionamide</mesh_term>
	<mesh_term>Streptomycin</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Kanamycin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>healthy male subject age 20 50 screen body weight range 55 kg ( inclusive ) 90 kg ( inclusive ) ideal body weight range 19.0 26.0 subject decide participate voluntarily write informed consent form subject clinically significant disease cardiovascular , respiratory , renal , endocrinological , hematological , gastrointestinal , neurological ( central nervous system ) , psychiatric disorder malignant tumor subject judge eligible study participation investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Antituberculosis agent</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>